| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $19.8M | — | -9.5% |
| Cost of Revenue | $4.9M | — | -42.8% |
| R&D Expense | $3.4M | — | +4.6% |
| SG&A Expense | $3.5M | — | -75.5% |
| Operating Income | $396K | — | +118.7% |
| Pre-tax Income | -$644K | — | +80.4% |
| Income Tax | -$149K | — | +86.3% |
| Net Income | -$495K | — | +77.5% |
| EPS (Basic) | -$0.03 | — | +75.0% |
| EPS (Diluted) | -$0.03 | — | +75.0% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $20.2M | -13.7% | +21.7% |
| Accounts Receivable | $32.0M | -15.3% | -2.2% |
| Current Assets | $56.2M | -13.2% | +8.6% |
| Total Assets | $167.3M | -5.5% | -0.3% |
| Current Liabilities | $10.5M | -50.8% | -43.0% |
| Long-term Debt | $23.6M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$467K | — | -112.1% |
| Capital Expenditures | $21K | — | -22.2% |
| Investing Cash Flow | -$21K | — | +75.0% |
| Financing Cash Flow | -$2.7M | — | -361.3% |
| Free Cash Flow | -$488K | — | -112.7% |
| -30.2% |
| Total Liabilities | $37.7M | -22.6% | -26.9% |
| Stockholders' Equity | $129.6M | +1.0% | +11.5% |